The unique biological dressing ‘Omnigen’ was originally developed by researchers in The University of Nottingham’s School of Medicine, work which led to the formation of a University spin-out company NuVision Biotherapies. Omnigen has the potential to revolutionise the treatment for emergency cases of ophthalmic wounds including abrasions, burns and more serious perforations, as well as planned operations on the eye.
NuVision has now been granted a full licence by the Human Tissue Authorityto distribute Omnigen, and patients coming for treatment at Nottingham University NHS Trust’s Queen’s Medical Centre are among the first to try this innovative new treatment.
The University of Nottingham
Queen's Medical Centre, B Floor, Eye and ENT
Nottingham, NG7 2UH
telephone: +44 (0) 115 97 09796
Connect with the University of Nottingham through social media and our blogs.
Campus maps | More contact information | Jobs
Browser does not support script.